[The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease].

MLA

Mukhin, N. A., et al. “[The Serum Level of the Morphogenetic Protein Fibroblast Growth Factor 23 (FGF-23) as a Marker for the Efficiency of Hyperphosphatemia Therapy with Phosphate-Binding Agents in Chronic Kidney Disease].” Terapevticheskii Arkhiv, vol. 88, no. 4, Jan. 2016, pp. 41–45. EBSCOhost, https://doi.org/10.17116/terarkh201688441-45.

APA

Mukhin, N. A., Milovanov, Y. S., Kozlovskaya, L. V., Dobrosmyslov, I. A., & Milovanova, L. Y. (2016). [The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease]. Terapevticheskii Arkhiv, 88(4), 41–45. https://doi.org/10.17116/terarkh201688441-45

Chicago

Mukhin, N A, Yu S Milovanov, L V Kozlovskaya, I A Dobrosmyslov, and L Yu Milovanova. 2016. “[The Serum Level of the Morphogenetic Protein Fibroblast Growth Factor 23 (FGF-23) as a Marker for the Efficiency of Hyperphosphatemia Therapy with Phosphate-Binding Agents in Chronic Kidney Disease].” Terapevticheskii Arkhiv 88 (4): 41–45. doi:10.17116/terarkh201688441-45.